ArriVent doses first patient in Phase 1 trial of ARR-002 for ovarian, endometrial cancer
AVBP•ArriVent dosed the first patient in a US Phase 1 trial of ARR-002 for ovarian and endometrial cancer. No clinical results have been presented; Shanghai Allist holds an exclusive license to develop and commercialize the drug in Greater China, while ArriVent retained rights elsewhere.
1. Trial begins
ArriVent dosed the first patient in a US Phase 1 trial of ARR-002 for ovarian and endometrial cancer. The dual-target antibody-drug conjugate is designed to target two tumor markers; no clinical results have been presented. Shanghai Allist holds an exclusive license to develop and commercialize ARR-002 in Greater China, and ArriVent retained rights elsewhere.
